Bayer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals, agricultural and material sciences.
Bayer Healthcare has an active licensing partnering group that combining expertise is key to innovation and success. Bayer has a long history of partnering, building numerous collaborative partnerships.
Complementing Bayer’s own capabilities by establishing long-term relationships with innovative partners from science and industry is an essential element of the company’s strategy.
Bayer recognize that they are not the only pharmaceutical company with expertise and specialized knowledge to discover breakthrough therapies. Each company or academic institution – be it a university, a small biotech firm or a large pharmaceutical corporation – has its own strengths and capabilities.
Bayer believe that by combining this expertise and knowledge they can successfully and sustainably contribute to improving therapies for the benefit of patients, partners, and themselves.
With a long-term tradition of successful partnerships all over the world, Bayer are committed to investing even more in accessing and advancing external innovations. With its different partners and global organization, Bayer work together in all phases of the value chain – from research to development and production to marketing.
A partnership entails much more than merely signing a deal.
What comes afterwards is just as important for the success of a partnership. Good cooperation is essential – on the executive management level as well as on the expert working level.
Bayer support every partnership with an alliance manager.
Alliance managers will take care of a joint project just as if it was their own project, making sure that the collaboration works smoothly to mutual benefit.
Like many companies, Bayer seeks to be ‘partner of choice’ in its target therapy and technology areas.
Summary of Bayer’s partnering interests
Bayer splits its partnering interests into distinct areas.
These can be summarized as follows:
- Licensing early stage discovery technologies as well as enabling platform technologies to support our core areas of interest. Bayer are committed to developing these technologies to enhance its internal small molecule and biologics drug discovery efforts.
- Strategic Partnerships with Academic Centers in core areas of therapeutic interest as well as with Pharmaceutical and Biotech Companies whose technologies are complimentary to internal expertise. Examples are partnerships with the German Cancer Research Center DKFZ in Heidelberg, the Tsinghua University in Beijing, and the National University of Singapore.
- Bayer embrace new models of open innovation and implemented the “Grants4Targets” initiative in 2009 aimed at research groups that have made substantial contributions in the discovery of new and innovative targets and require further funding for adequate validation. The initiative has funded over 40 projects in our core areas of therapeutic research.
- Bayer are interested in collaborative models of open innovation and will work together with partners to develop promising targets and technologies by leveraging internal strengths and expertise to compliment the partners. One example is engagement in the Innovative Medicines Initiative IMI
- Bayer seek novel small molecule and biologic candidates for in-licensing from pre-clinical leads to clinical development candidates. Bayer will work to advance these candidates to achieve Proof of Concept with its long-standing expertise in drug development.
Bayer’s areas of interest for partnering are summarized as follows:
Source: Bayer website, 2013
For the latest detail on Bayer’s partnering interests, visit the partnering section of Bayer’s website > go to Partnering for details.
Bayer are routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with Bayer presence include but are not limited to:
- BIO International Convention and Business Forum
- BioPartnering Future Europe / BioPartnering North America
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Bayer in person visit Current Partnering’s Event calendar.
In addition, you can find a full list of events where Bayer will be present for partnering discussions, visit the partnering section of Bayer’s website > go to Partnering for details.
Contacting Bayer for partnering
Bayer can be contacting in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
- Direct contact: there are several sources of direct contact with Bayer’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Bayer do not publish a list of contacts on their website, so unless you cannot find a direct contact elsewhere use the contact form here.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of Bayer’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Bayer’s LinkedIn page here
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. Bayer provides an online opportunity submission form which can be found by partnering section of Bayer’s website > go to Partnering for details.
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Bayer
Available resources for deal coverage for Bayer
Read: more on Bayer company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk